Humana Inc. (NYSE:HUM) announced a quarterly dividend on Thursday, August 25th. Investors of record on Thursday, October 13th will be paid a dividend of 0.29 per share by the insurance provider on Friday, October 28th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Tuesday, October 11th.

Shares of Humana (NYSE:HUM) opened at 177.80 on Thursday. Humana has a 52 week low of $150.00 and a 52 week high of $191.65. The company has a market capitalization of $26.50 billion, a PE ratio of 27.32 and a beta of 0.90. The company’s 50 day moving average is $176.90 and its 200-day moving average is $176.10.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 3rd. The insurance provider reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.23 by $0.07. The business had revenue of $14 billion for the quarter, compared to analysts’ expectations of $13.59 billion. Humana had a return on equity of 11.11% and a net margin of 1.76%. Humana’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.67 earnings per share. On average, analysts expect that Humana will post $9.24 EPS for the current fiscal year.

A number of analysts have weighed in on the company. Cantor Fitzgerald reiterated a “buy” rating on shares of Humana in a research report on Saturday, July 9th. RBC Capital Markets reiterated a “buy” rating and issued a $224.00 price target (up from $220.00) on shares of Humana in a research report on Friday, July 22nd. Credit Suisse Group AG reiterated a “hold” rating and issued a $188.00 price target on shares of Humana in a research report on Tuesday, September 13th. Jefferies Group reiterated a “buy” rating and issued a $220.00 price target (up from $210.00) on shares of Humana in a research report on Monday, July 25th. Finally, Barclays PLC lowered their price target on Humana from $193.00 to $191.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 4th. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $201.00.

Several hedge funds and other institutional investors have recently bought and sold shares of HUM. Point72 Asia Hong Kong Ltd bought a new position in Humana during the second quarter worth $126,000. Bessemer Group Inc. increased its position in Humana by 14.0% in the second quarter. Bessemer Group Inc. now owns 1,140 shares of the insurance provider’s stock worth $205,000 after buying an additional 140 shares in the last quarter. Argent Trust Co increased its position in Humana by 16.9% in the second quarter. Argent Trust Co now owns 1,574 shares of the insurance provider’s stock worth $283,000 after buying an additional 228 shares in the last quarter. Johnson Investment Counsel Inc. increased its position in Humana by 6.4% in the second quarter. Johnson Investment Counsel Inc. now owns 1,988 shares of the insurance provider’s stock worth $357,000 after buying an additional 119 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. bought a new position in Humana during the second quarter worth $442,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

5 Day Chart for NYSE:HUM

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.